Elekta Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Los beneficios de Elekta han disminuido a una tasa media anual de -1.2%, mientras que en la industria Medical Equipment los beneficios disminuyeron en un 5.9% anualmente. Los ingresos han ido creciendo a una tasa media de 5.3% al año. La rentabilidad financiera de Elekta es de 14%, y sus márgenes netos son de 7.9%.

Información clave

-1.2%

Tasa de crecimiento de los beneficios

-1.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	-9.5%
Tasa de crecimiento de los ingresos	5.3%
Rentabilidad financiera	14.0%
Margen neto	7.9%
Próxima actualización de resultados	05 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Elekta. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:0O5H Ingresos, gastos y beneficios (SEK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Jan 24	18,221	1,433	3,058	1,350
31 Oct 23	18,021	1,344	3,050	1,330
31 Jul 23	17,370	1,121	3,041	1,368
30 Apr 23	16,869	943	3,001	1,369
31 Jan 23	15,984	813	2,818	1,394
31 Oct 22	15,249	826	2,803	1,419
31 Jul 22	14,866	1,087	2,646	1,368
30 Apr 22	14,548	1,154	2,528	1,372
31 Jan 22	13,976	1,079	2,444	1,384
31 Oct 21	13,955	1,172	2,334	1,424
31 Jul 21	13,791	1,165	2,268	1,491
30 Apr 21	13,763	1,254	2,229	1,486
31 Jan 21	14,104	1,321	2,254	1,536
31 Oct 20	14,179	1,307	2,340	1,573
31 Jul 20	14,354	1,153	2,453	1,612
30 Apr 20	14,601	1,084	2,537	1,657
31 Jan 20	14,680	1,212	2,540	1,679
31 Oct 19	14,343	1,115	2,476	1,663
31 Jul 19	13,964	1,179	2,381	1,658
30 Apr 19	13,555	1,198	2,335	1,592
31 Jan 19	12,877	1,164	2,278	1,409
31 Oct 18	12,315	1,295	2,230	1,273
31 Jul 18	11,888	1,315	2,198	1,144
30 Apr 18	11,573	1,348	2,157	1,095
31 Jan 18	11,879	939	2,125	1,147
31 Oct 17	11,795	639	2,129	1,144
31 Jul 17	11,326	389	2,150	1,083
30 Apr 17	10,704	125	2,093	1,018
31 Jan 17	10,596	108	2,139	977
31 Oct 16	10,470	70	2,200	991
31 Jul 16	10,864	203	2,238	1,044
30 Apr 16	11,221	137	2,362	1,065
31 Jan 16	11,469	402	2,548	1,070
31 Oct 15	11,474	548	2,526	1,022
31 Jul 15	11,213	558	2,485	974
30 Apr 15	10,839	552	2,383	952
31 Jan 15	10,938	1,029	2,097	904
31 Oct 14	10,771	1,026	2,027	902
31 Jul 14	10,647	1,017	1,999	896
30 Apr 14	10,694	1,148	1,974	866
31 Jan 14	10,471	1,173	1,964	805
31 Oct 13	10,514	1,256	1,993	778
31 Jul 13	10,556	1,322	2,019	736

Ingresos de calidad: 0O5H tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (7.9%) de 0O5H son superiores a los del año pasado (5.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 0O5H han disminuido en un 1.2% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 0O5H en el último año (76.3%) supera su media de 5 años (-1.2% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 0O5H en el último año (76.3%) superó al de la industria Medical Equipment 17.9%.

Elekta Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023)

Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024

Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023)

Elekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024

First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023)

Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)

Recent updates

Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the Board

Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023)

Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024

Upcoming dividend of kr1.20 per share

Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023)

Elekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024

Elekta AB (publ) Announces Composition of Nomination Committee

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

Elekta AB (publ), Annual General Meeting, Sep 05, 2024

Founder & Chairman recently sold kr60m worth of stock

First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023)

Elekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, Respectively

Upcoming dividend of kr1.20 per share at 3.1% yield

Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)

President & CEO recently bought kr501k worth of stock

Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)

Now 20% undervalued

Elekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024

Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022)

Elekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025

Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONE

Third quarter 2023 earnings released

Upcoming dividend of kr1.20 per share at 3.1% yield

Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.

Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.

Independent Director recently bought kr63k worth of stock

First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-Linac

Second quarter 2023 earnings released

Elekta AB (publ), Annual General Meeting, Aug 24, 2023

Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain Disease

Insufficient new directors

Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) Clearance

Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual Meeting

Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD)

Elekta AB (publ) Elects Kelly Londy as a Director

First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022)

Upcoming dividend of kr1.20 per share

Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)

Elekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023

Chief Product Officer recently bought kr420k worth of stock

Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021)

Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22

Elekta Launches New Radiosurgery System: Elekta Esprit

Insufficient new directors

Elekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022

Insider recently bought kr518k worth of stock

Third quarter 2022 earnings: Revenues in line with analyst expectations

Elekta AB (publ), Annual General Meeting, Aug 25, 2022

Investor sentiment deteriorated over the past week

Upcoming dividend of kr1.10 per share

President of Brachy Solutions recently bought kr305k worth of stock

Independent Director recently bought kr1.1m worth of stock

Second quarter 2022 earnings: Revenues exceed analyst expectations

Founder & Chairman recently bought kr49m worth of stock

Elekta AB (publ) (OM:EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S.

First quarter 2022 earnings released: EPS kr0.33 (vs kr0.56 in 1Q 2021)

Upcoming dividend of kr1.10 per share

Full year 2021 earnings released: EPS kr3.28 (vs kr2.84 in FY 2020)

President & CEO recently bought kr1.0m worth of stock

Elekta AB (Publ)'s Elekta Harmony Radiation Therapy System Receives U.S. FDA 510(K) Clearance

CFO & Group Treasurer recently bought kr492k worth of stock

Full year 2021 earnings released: EPS kr3.28 (vs kr2.84 in FY 2020)

Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021

Elekta AB (Publ) Approves Extra Dividend, Payable on 23 April 2021

Elekta AB (publ) Proposes Extra Dividend, Payable on 23 April 2021

Elekta and IBA Strengthen Partnership to Help Cancer Centers Integrate Proton Therapy

Elekta Not Provides Earnings Guidance for the Year of 2021

First Cancer Centers Begin Using Initial Release of Elekta's MOSAIQ 3 Series

Elekta AB (publ) (OM:EKTA B) signed an agreement to acquire Oncology division from Horizon for Medical Appliances.

Desglose de ingresos y gastos
Beta